Substituted cathinone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Script error: No such module "Unsubst".

File:Cathinone.svg
Cathinone
File:Substituted cathinone.svg
General chemical structure of substituted cathinones, with R1-R4 defined in text

Substituted cathinones, or simply cathinones, which include some stimulants and entactogens, are derivatives of cathinone. They feature a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon, along with additional substitutions.[1][2][3][4][5] Cathinone occurs naturally in the plant khat whose leaves are chewed as a recreational drug.[6]

Substituted cathinones act as monoamine releasing agents and/or monoamine reuptake inhibitors, including of norepinephrine, dopamine, and/or serotonin.[7][8][9][10][11][12] In contrast to substituted amphetamines, most substituted cathinones do not act as agonists of the human trace amine-associated receptor 1 (TAAR1).[13][14][15] This may potentiate their stimulating and addictive effects.[13][14] In addition, β-keto-substituted phenethylamines, such as βk-2C-B, appear to show dramatically reduced potency and efficacy as serotonin 5-HT2A receptor agonists compared to their non-β-keto-substituted counterparts.[16]

Monoamine release profiles

The following is a list of serotonin, dopamine, and norepinephrine releasing profiles for various cathinones, measured in rat brain synaptosomes.[7][8][17]

Template:Sticky

List of substituted cathinones

The derivatives may be produced by substitutions at four locations of the cathinone molecule:

  • R1 = hydrogen, or any combination of one or more alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents
  • R2 = hydrogen or any alkyl group
  • R3 = hydrogen, any alkyl group, or incorporation in a cyclic structure
  • R4 = hydrogen, any alkyl group, or incorporation in a cyclic structure

The following table displays notable derivatives that have been reported:[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76]

Template:Sticky

Legality

On 2 April 2010, the Advisory Council on the Misuse of Drugs in the UK announced that a broad structure-based ban of this entire class of compounds would be instituted, following extensive publicity around grey-market sales and recreational use of mephedrone, a common member of the family. This ban covers compounds with the aforementioned general structure, with 28 compounds specifically named.[77]

<templatestyles src="Template:Blockquote/styles.css" />

"Any compound (not being bupropion or a substance for the time being specified in paragraph 2.2) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say,

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii) by substitution at the 3-position with an alkyl substituent;

(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure."

Script error: No such module "Check for unknown parameters".

This text was added as an amendment to the Misuse of Drugs Act 1971, to come into force on 16 April 2010.[78] Note that four of the above compounds (cathinone, methcathinone, diethylpropion and pyrovalerone) were already illegal in the UK at the time the ACMD report was issued. Two compounds were specifically excluded from the ban, these being bupropion because of its common use in medicine and relative lack of abuse potential, and naphyrone because its structure falls outside the generic definition and not enough evidence was yet available to justify a ban.

Naphyrone analogues were subsequently banned in July 2010 following a further review by the ACMD,[79][80] along with a further broad based structure ban even more expansive than the last.[81][82]

<templatestyles src="Template:Blockquote/styles.css" />

"Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is

further modified in any of the following ways, that is to say—

(i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or

by inclusion of the 2-amino nitrogen atom in a cyclic structure".

Script error: No such module "Check for unknown parameters".

File:Naphyrone general.png
General chemical structure of substituted naphyrones, with R1-R3 defined in text

The substitutions in the general structure for naphyrone analogues subject to the ban may be described as follows:

  • Cyc = any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), including analogues where the ring system is substituted to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents
  • R1 = hydrogen or any alkyl group
  • R2 = hydrogen, any alkyl group, or incorporation in a cyclic structure
  • R3 = hydrogen, any alkyl group, or incorporation in a cyclic structure

More new derivatives have however continued to appear, with the UK reporting more novel cathinone derivatives detected in 2010 than any other country in Europe, with most of them first identified after the generic ban had gone into effect and thus already being illegal despite never having been previously reported.[83]

In the United States, substituted cathinones are the psychoactive ingredients in "bath salts" which as of July 2011 were banned by at least 28 states, but not by the federal government.[84]

See also

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "Citation/CS1".
  2. Script error: No such module "Citation/CS1".
  3. Script error: No such module "Citation/CS1".
  4. Script error: No such module "Citation/CS1".
  5. Script error: No such module "Citation/CS1".
  6. Script error: No such module "Citation/CS1".
  7. a b c Script error: No such module "Citation/CS1".
  8. a b c Script error: No such module "Citation/CS1".
  9. a b c Script error: No such module "Citation/CS1".
  10. Script error: No such module "Citation/CS1".
  11. Script error: No such module "Citation/CS1".
  12. a b c Script error: No such module "Citation/CS1".
  13. a b Script error: No such module "Citation/CS1".
  14. a b Script error: No such module "Citation/CS1".
  15. Script error: No such module "Citation/CS1".
  16. Script error: No such module "Citation/CS1".
  17. a b c d e Script error: No such module "citation/CS1".
  18. a b c d e f g h i j k l m n o p Script error: No such module "Citation/CS1".
  19. a b c d e f g h i j k l m n o p q r s t u Script error: No such module "Citation/CS1".
  20. a b c Script error: No such module "Citation/CS1".
  21. a b c Script error: No such module "Citation/CS1".
  22. a b c d e f g h i j k l m n Script error: No such module "Citation/CS1".
  23. Script error: No such module "citation/CS1".
  24. a b c d e f g h i j k Script error: No such module "citation/CS1".
  25. a b c Script error: No such module "Citation/CS1".
  26. Script error: No such module "citation/CS1".
  27. Script error: No such module "Citation/CS1".
  28. a b c Script error: No such module "citation/CS1".
  29. <templatestyles src="Citation/styles.css"/>Template:Citation/make link, Matthew J. Baggott & Sean Dalziel, "Specialized combinations for mental disorders or mental enhancement", published Script error: No such module "auto date formatter"., assigned to Tactogen Inc. Script error: No such module "Check for unknown parameters".
  30. a b c d e Script error: No such module "Citation/CS1".
  31. a b c d e f g h Script error: No such module "citation/CS1".
  32. a b c d e f Script error: No such module "Citation/CS1".
  33. a b c d e f Script error: No such module "Citation/CS1".
  34. Script error: No such module "citation/CS1".
  35. a b c d e f g h Script error: No such module "citation/CS1".
  36. Script error: No such module "Citation/CS1".
  37. Script error: No such module "Citation/CS1".
  38. Script error: No such module "Citation/CS1".
  39. a b c Script error: No such module "citation/CS1".
  40. a b Script error: No such module "Citation/CS1".
  41. Script error: No such module "citation/CS1".
  42. a b Script error: No such module "Citation/CS1".
  43. Script error: No such module "Citation/CS1".
  44. Script error: No such module "Citation/CS1".
  45. a b c d e Script error: No such module "Citation/CS1".
  46. Script error: No such module "Citation/CS1".
  47. a b c d Script error: No such module "Citation/CS1".
  48. Script error: No such module "Citation/CS1".
  49. a b Script error: No such module "Citation/CS1".
  50. a b c d Script error: No such module "Citation/CS1".
  51. a b Script error: No such module "Citation/CS1".
  52. a b Script error: No such module "Citation/CS1".
  53. Script error: No such module "Citation/CS1".
  54. Script error: No such module "Citation/CS1".
  55. Europol 2008 Annual Report on the implementation of Council Decision 2005/387/JHA
  56. Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA
  57. Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA
  58. Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA
  59. Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA
  60. Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA
  61. Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA
  62. Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
  63. Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA
  64. Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA
  65. Script error: No such module "citation/CS1".
  66. Script error: No such module "Citation/CS1".
  67. Script error: No such module "Citation/CS1".
  68. Script error: No such module "Citation/CS1".
  69. Script error: No such module "Citation/CS1".
  70. Script error: No such module "Citation/CS1".
  71. Script error: No such module "Citation/CS1".
  72. Script error: No such module "Citation/CS1".
  73. Script error: No such module "Citation/CS1".
  74. Script error: No such module "Citation/CS1".
  75. Script error: No such module "Citation/CS1".
  76. Script error: No such module "citation/CS1".
  77. Advisory Council on the Misuse of Drugs (UK). Consideration of the cathinones. 31 March 2010. Script error: No such module "webarchive". Retrieved 2011-07-17.
  78. Script error: No such module "citation/CS1".
  79. Script error: No such module "citation/CS1".
  80. Script error: No such module "citation/CS1".
  81. Script error: No such module "citation/CS1".
  82. Script error: No such module "citation/CS1".
  83. European Monitoring Centre on Drugs and Drug Addiction. EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA. Script error: No such module "webarchive". Retrieved 2011-07-17.
  84. Script error: No such module "citation/CS1".

Script error: No such module "Check for unknown parameters".

External links

  • Script error: No such module "citation/CS1".

Script error: No such module "Navbox". Template:Chemical classes of psychoactive drugs Template:Monoamine releasing agents Template:Monoamine reuptake inhibitors